Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse® (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF).
Incorporating preoperative right heart measurements into the standard pulmonary hypertension risk estimation model may allow for better risk stratification following aortic valve replacement.
Pulmonary hypertension can be a severe and potentially debilitating complication in patients with chronic left-sided heart failure.
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
Bellerophon Therapeutics announced positive topline results from cohort 2 of an ongoing phase 2/3 iNO-PF study of INOpulse delivery system for the treatment of PH-ILD.
Cardiac magnetic resonance imaging is useful for risk stratification in patients with pulmonary arterial hypertension.
A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension.
Treatment with noninvasive ventilation and continuous positive airway pressure provided similar improvements in pulmonary hypertension and left ventricular diastolic dysfunction in obesity hypoventilation syndrome and concomitant severe obstructive sleep apnea.
In patients with pulmonary arterial hypertension, cardiac magnetic resonance imaging metrics are capable of identifying individuals at a low risk for 1-year mortality.
This study assessed improvement in pulmonary vascular resistance and cardiac index in patients with pulmonary arterial hypertension who rapidly inhale iloprost 2.5 ug via the Breelib™ nebulizer.
